Revance Therapeutics announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to RT002 (daxibotulinumtoxinA for injection) to treat adults with cervical dystonia.
Phase 2 clinical data showed RT002 was safe and well-tolerated while providing a long-lasting improvement of patients’ symptoms. Botulinum toxins work by blocking communication between the nerve and muscle, which may alleviate abnormal movements and postures.
DaxibotulinumtoxinA is being developed for a range of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders; it has the potential to be the first FDA-approved long-acting neuromodulator. Specifically, it is being developed for the treatment of glabellar lines, cervical dystonia, and plantar fasciitis.
For more information call (510) 742-3400 or visit Revance.com.